Drugs / Veonetinib
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05363280 | Nov 2022 → Dec 2027 expected | non-small cell lung carcinoma, renal cell carcinoma, small cell lung carcinoma | Advenchen Pharmaceuticals, LLC. | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Veonetinib | “A Phase 2 Evaluation of the Safety and Efficacy of Veonetinib (AL8326) in ≥2nd Line Small Cell Lung Cancer (SCLC), Non-Small Cell Lung Cancer (NSCLC) and Renal Cell Carcinoma...” NCT05363280 ↗ |
| Known as | AL8326 | “A Phase 2 Evaluation of the Safety and Efficacy of Veonetinib (AL8326) in ≥2nd Line Small Cell Lung Cancer (SCLC), Non-Small Cell Lung Cancer (NSCLC) and Renal Cell Carcinoma...” NCT05363280 ↗ |
| Action | Inhibit | “a multi-targeted receptor Tyrosine Kinase Inhibitor( TKI)” NCT05363280 ↗ |
| Modality | Small molecule | “a multi-targeted receptor Tyrosine Kinase Inhibitor( TKI)” NCT05363280 ↗ |
| Route | Oral | “using oral AL8326” NCT05363280 ↗ |